Clinical Anslysis of Primary Adrenal NK/T-Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2023.02.013
- Author:
Xin-Yue JI
1
;
Da-Peng SHENG
1
;
Yu-Qiong YANG
1
;
Yuan-Feng WEI
1
;
Xi HUANG
1
;
Qiong LIU
1
;
Dan-Ning YU
1
;
Yu-Xin GUO
1
;
He-Sheng HE
2
Author Information
1. Department of Hematology, Yijishan Hospital of Wannan Medical College, Wuhu 241000, Anhui Province, China.
2. Department of Hematology, Yijishan Hospital of Wannan Medical College, Wuhu 241000, Anhui Province, China .E-mail: hhsmed2012@126.com.
- Publication Type:Journal Article
- Keywords:
etoposide;
hemophagocytic syndrome;
sintilimab;
primary adrenal natural killer/T-cell lymphoma
- MeSH:
Humans;
Treatment Outcome;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Retrospective Studies;
Etoposide;
Neoplasm Recurrence, Local/drug therapy*;
Asparaginase;
Deoxycytidine;
Lymphoma, T-Cell, Peripheral/drug therapy*;
Lymphoma, Extranodal NK-T-Cell/therapy*;
Oxaliplatin/therapeutic use*
- From:
Journal of Experimental Hematology
2023;31(2):396-402
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical characteristics, diagnosis, and treatment of one patient with primary adrenal natural killer/T-cell lymphoma (PANKTCL), and to strengthen the understanding of this rare type of lymphoma.
METHODS:The clinical manifestations, diagnosis and treatment process, and prognosis of the patient admitted in our hospital were retrospectively analyzed.
RESULTS:Combined with pathology, imaging, bone marrow examination， etc, the patient was diagnosed with PANKTCL (CA stage, stage II; PINK-E score 3, high-risk group). Six cycles of "P-GemOx+VP-16" regimen（gemcitabine 1 g/m2 d1 + oxaliplatin 100 mg/m2 d 1 + etoposide 60 mg/m2 d 2-4 + polyethylene glycol conjugated asparaginase 3 750 IU d 5） was performed, and complete response was assessed in 4 cycles. Maintenance therapy with sintilimab was administered after the completion of chemotherapy. Eight months after the complete response, the patient experienced disease recurrence and underwent a total of four courses of chemotherapy, during which hemophagocytic syndrome occurred. The patient died of disease progression 1 month later.
CONCLUSION:PANKTCL is rare, relapses easily, and has a worse prognosis. The choice of the "P-GemOx+VP-16" regimen combined with sintilimab help to improve the survival prognosis of patient with non-upper aerodigestive tract natural killer /T-cell lymphoma.
